OneSource Specialty Pharma Ltd

OneSource Speci. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

OneSource Specialty Pharma Ltd

₹ 1,549 0.37%
20 Apr 3:57 p.m.
onesourcecdmo.com BSE: 544292 NSE: ONESOURCE
About

Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]

Key Points

Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.

Website BSE NSE
  • Market Cap ₹ 17,793 Cr.
  • Current Price ₹ 1,549
  • High / Low ₹ 2,250 / 1,057
  • Stock P/E 582
  • Book Value ₹ 515
  • Dividend Yield 0.00 %
  • ROCE 5.53 %
  • ROE 3.34 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is expected to give good quarter

Cons

  • Stock is trading at 3.01 times its book value
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -17.7% over last 3 years.
  • Debtor days have increased from 86.2 to 105 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE 250 SmallCap Index BSE 400 MidSmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
34 56 73 292 334 393 426 327 376 290
72 67 76 228 257 251 243 239 269 273
Operating Profit -39 -10 -3 64 77 142 183 88 106 17
OPM % -114% -19% -4% 22% 23% 36% 43% 27% 28% 6%
-32 -74 3 -1 -1 -94 2 2 3 -2
Interest 25 26 20 42 45 46 33 27 34 38
Depreciation 18 20 20 68 68 69 68 68 70 70
Profit before tax -114 -130 -40 -47 -37 -67 83 -4 6 -93
Tax % 0% 0% 0% -88% 12% 4% -19% -96% -83% -5%
-114 -130 -40 -6 -42 -69 98 -0 10 -89
EPS in Rs -6.02 8.61 -0.02 0.92 -7.74
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
21 128 39 172 1,445 1,419
93 132 199 235 978 1,025
Operating Profit -71 -4 -161 -63 467 395
OPM % -334% -3% -415% -37% 32% 28%
1 -128 -526 -143 -94 5
Interest 16 46 48 89 166 133
Depreciation 34 53 66 95 274 276
Profit before tax -121 -231 -800 -391 -68 -9
Tax % 0% -0% 0% 0% -73%
-121 -231 -800 -391 -18 20
EPS in Rs -1.57 1.77
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 124%
TTM: 30%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 35%
TTM: 157%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -1%
Return on Equity
10 Years: %
5 Years: -19%
3 Years: -18%
Last Year: 3%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 2 3 4 4 11 11
Reserves 774 1,009 781 392 5,869 5,893
386 1,182 864 562 772 1,295
96 248 365 468 1,005 814
Total Liabilities 1,258 2,442 2,015 1,426 7,657 8,013
633 1,231 1,361 863 6,118 6,286
CWIP 431 490 334 188 218 173
Investments 0 0 4 20 16 20
195 722 314 356 1,305 1,535
Total Assets 1,258 2,442 2,015 1,426 7,657 8,013

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-118 -416 -163 -107 -68
-207 -692 -68 511 -201
381 1,162 118 -391 412
Net Cash Flow 56 54 -112 13 143
Free Cash Flow -325 -1,071 -207 -171 -196
CFO/OP 164% 10,397% 108% 169% -13%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 38 67 36 117 105
Inventory Days 87 615 258 222
Days Payable 762 420 163 147
Cash Conversion Cycle -637 67 232 212 180
Working Capital Days -2,392 -1,331 -6,745 -877 -58
ROCE % -3% -12% -12% 6%

Insights

In beta
Mar 2024 Mar 2025 Mar 2026 Mar 2028 (P)
Cartridge Production Capacity
Million Units

Log in to view insights

Please log in to see hidden values.

Login
Pre-filled Syringes (PFS) Capacity
Million Units
Total Workforce (FTEs)
Number
Vial Production Capacity
Million Units
Biologics Mammalian Capacity
KL
Biologics Microbial Capacity
KL
Customer Advances for DDC Capacity
INR Million
NCE-1 and NBE Programs
Number
Biologics Funnel (New projects)
Number
Developed & Approved ANDAs
Number
GLP-1 Customers
Number
Number of Global Customers
Number
Number of Manufacturing Plants
Number
Successful Regulatory/Customer Audits
Number
Technology Transfer Batches Delivered
Number
Total Successful Audits (Cumulative)
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

12 Recently
Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
37.76% 34.25% 29.78% 29.77% 29.93%
17.44% 18.54% 18.69% 19.39% 19.24%
12.56% 18.03% 18.09% 18.48% 18.80%
32.24% 29.17% 33.42% 32.34% 32.01%
No. of Shareholders 98,42582,71287,76087,41684,595

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls